Nuvation Bio Completes $287.5M Convertible Note Offering with Full Greenshoe Exercise
NUVB has more than doubled off its 52-week low of $2.01.
Summary
Nuvation Bio announced the full exercise of the over-allotment option for its convertible senior notes, increasing the total offering size to $287.5 million and securing approximately $277.6 million in net proceeds.
Key Events · Financing and Capital Events · NUVB
-
Greenshoe Option Fully Exercised
Underwriters fully exercised the over-allotment option for an additional $37.5 million in 0.75% Convertible Senior Notes due 2032.
-
Total Offering Reaches $287.5 Million
The full exercise brings the total aggregate principal amount of notes sold in the offering to $287.5 million, up from the initial $250 million.
-
Net Proceeds of $277.6 Million
The company estimates net proceeds from the total offering, inclusive of the greenshoe, to be approximately $277.6 million after deducting expenses.
-
Dilution Mitigation via Capped Calls
Nuvation Bio entered into additional capped call transactions with a cap price of $10.4580 per share (an 80.0% premium over the June 25th stock price) to reduce potential dilution upon conversion.
Analysis · NUVB · Life Sciences
This 8-K finalizes Nuvation Bio's significant capital raise, confirming the full $287.5 million in convertible senior notes after underwriters exercised their greenshoe option. The additional $37.5 million in proceeds, combined with the initial offering, provides substantial funding for general corporate purposes. The low interest rate, high conversion premium, and capped call transactions help mitigate potential dilution, making this a relatively favorable financing for the company.
At the time of this filing, NUVB was trading at $5.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.01 to $9.75. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.